These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35971530)

  • 1. Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies.
    Karasavvidou EM; Tranos P; Panos GD
    Drug Des Devel Ther; 2022; 16():2659-2680. PubMed ID: 35971530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies.
    Panos GD; Lakshmanan A; Dadoukis P; Ripa M; Motta L; Amoaku WM
    Drug Des Devel Ther; 2023; 17():2861-2873. PubMed ID: 37746113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 5. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
    Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
    Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
    Bulirsch LM; Saßmannshausen M; Nadal J; Liegl R; Thiele S; Holz FG
    Br J Ophthalmol; 2022 Sep; 106(9):1288-1294. PubMed ID: 33846161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.
    Ferrante N; Ritrovato D; Bitonti R; Furneri G
    BMC Health Serv Res; 2022 Apr; 22(1):573. PubMed ID: 35484540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE).
    Garweg JG
    Klin Monbl Augenheilkd; 2020 Apr; 237(4):450-453. PubMed ID: 32131127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Angermann R; Huber AL; Nowosielski Y; Salcher S; Gasser T; Seifarth C; Kralinger MT; Zehetner C
    Retina; 2022 Mar; 42(3):503-510. PubMed ID: 34731094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data.
    Agostini H; Mulyukov Z; Tsilimbaris M; Calvo P; Bucher F; Gaucher D; Pigeolet E; Colafrancesco V; Clemens A
    Curr Eye Res; 2020 Oct; 45(10):1298-1301. PubMed ID: 32065533
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.
    Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S
    Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brolucizumab for the treatment of diabetic macular edema.
    Kuo BL; Singh RP
    Curr Opin Ophthalmol; 2022 May; 33(3):167-173. PubMed ID: 35266896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration.
    Brown DM; Nowik M; Bouillaud E; Dugel APU;
    Curr Eye Res; 2023 Jan; 48(1):44-50. PubMed ID: 36398628
    [No Abstract]   [Full Text] [Related]  

  • 16. Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data.
    Radke NV; Mohamed S; Brown RB; Ibrahim I; Chhablani J; Amin SV; Tsang CW; Brelen ME; Raichand NS; Fang D; Zhang S; Dai H; Chen GLJ; Cheung CMG; Hariprasad SM; Das T; Lam DSC
    Asia Pac J Ophthalmol (Phila); 2023 Mar-Apr 01; 12(2):168-183. PubMed ID: 36971706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD.
    Ferro Desideri L; Traverso CE; Nicolò M
    Expert Opin Biol Ther; 2021 May; 21(5):553-561. PubMed ID: 33899632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
    Shigemoto Y; Sakurada Y; Fukuda Y; Matsubara M; Parikh R; Kashiwagi K
    Medicine (Baltimore); 2021 Oct; 100(42):e27580. PubMed ID: 34678906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.